Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
Xiujuan Liu, Xu-Liu, Xiaojing Pang, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 47, pp. 116358-116358
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 79
Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy
Xiujuan Liu, Hong-Cheng Zhao, Su-Juan Hou, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106425-106425
Closed Access | Times Cited: 64
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 42
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 34
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 5, pp. 103312-103312
Open Access | Times Cited: 27
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
Franz Felix Konen, Nora Möhn, Torsten Witte, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 4, pp. 103754-103754
Closed Access
Design of a MIP-based electrochemical sensor for sensitive and selective detection of anti-cancer drug ibrutinib in pharmaceutical dosage forms and biological fluids
Tanzeel Arif, Ahmet Çetinkaya, Mehmet Altay Ünal, et al.
Journal of Pharmaceutical and Biomedical Analysis Open (2025), pp. 100055-100055
Open Access
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Maciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Blood Advances (2023) Vol. 7, Iss. 14, pp. 3531-3539
Open Access | Times Cited: 15
PROTACs in the Management of Prostate Cancer
Yedla Poornachandra, Ahmad O. Babalghith, Vindhya Vasini Andra, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3698-3698
Open Access | Times Cited: 15
Recent development of BTK-based dual inhibitors in the treatment of cancers
Fansheng Ran, Yun Liu, Zhongyuan Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114232-114232
Closed Access | Times Cited: 19
Highly selective electrochemical sensor for new generation targeted-anticancer drug Ibrutinib using newly synthesized nanomaterial GO-NH-B(OH)2@AgNPs modified glassy carbon electrode
Karina Amudi, Aybek Yiğit, Nurettin Mengeş, et al.
Measurement (2023) Vol. 216, pp. 112978-112978
Closed Access | Times Cited: 10
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
Zhaozhao Wang, S. Qu, Jiahao Yuan, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117514-117514
Closed Access | Times Cited: 9
Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis
Constantin A Dasanu, S.K. Mann, Melvin Baidya, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 11, pp. 1525-1540
Closed Access | Times Cited: 2
Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
Debasis Das, Jingbing Wang, Jian Hong
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 20, pp. 1674-1691
Closed Access | Times Cited: 11
The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS
Mengming Xia, Ya�nan Liu, Jie Chen, et al.
Current Medicinal Chemistry (2024) Vol. 31, Iss. 34, pp. 5612-5619
Closed Access | Times Cited: 1
Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells.
Ruyu Fan, Shipeng He, Yongqing Wang, et al.
PubMed (2022) Vol. 12, Iss. 3, pp. 1027-1041
Closed Access | Times Cited: 9
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China
Danling Gu, Jianyong Li, Yi Miao
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 1979-1986
Closed Access | Times Cited: 9
Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry
Shengnan Ji, Xiaomeng Liu, Jing Ha, et al.
Journal of Chromatography B (2023) Vol. 1221, pp. 123680-123680
Closed Access | Times Cited: 4
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies
Paweł Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1065-1076
Closed Access | Times Cited: 4
Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
Lei Ding, Ping Zhang, Xu Huang, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 7
Using a Boron‐Doped Diamond Electrode in Anionic Surfactant Media as an Improved Electrochemical Sensor for the Anticancer Drug Ibrutinib
Cihat Mete, Pınar Talay Pınar
ChemistrySelect (2023) Vol. 8, Iss. 6
Closed Access | Times Cited: 3
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia
Fansheng Ran, Yun Liu, Jian Zhu, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106479-106479
Closed Access | Times Cited: 3
Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects
Fansheng Ran, Xudong Xie, Qilin Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 245, pp. 114913-114913
Closed Access | Times Cited: 5
Strategies for the Synthesis of Heterocycles and Their Applications
Premlata Kumari, Rohit Singh, Avneet Kaur, et al.
IntechOpen eBooks (2022)
Open Access | Times Cited: 4
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas
Peiran Song, Zhi-peng Wan, Gege Huang, et al.
Acta Pharmacologica Sinica (2024)
Closed Access
Page 1 - Next Page

Scroll to top